Informační systém MU
ŠTARK, Tibor, Martina DI BARTOLOMEO, Roberta DI MARCO, Eva DRAŽANOVÁ, Chiara Bianca Maria PLATANIA, Fabio Arturo IANNOTTI, Jana RUDÁ, Claudio D'ADDARIO, Lucie KRATKA, Vladimír PEKAŘÍK, Fabiana PISCITELLI, Zuzana BABINSKÁ, Julia FEDOTOVA, Giovanni GIURDANELLA, Salvatore SALOMONE, Alexandra SULCOVA, Claudio BUCOLO, Carsten T. WOTJAK, Zenon, Jr. STARCUK, Filippo DRAGO, Raphael MECHOULAM, Vincenzo DI MARZO and Vincenzo MICALE. Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment. Biochemical Pharmacology. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD, 2020, vol. 177, July 2020, p. 1-12. ISSN 0006-2952. Available from: https://dx.doi.org/10.1016/j.bcp.2020.114004.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment
Authors ŠTARK, Tibor (703 Slovakia, belonging to the institution), Martina DI BARTOLOMEO (380 Italy), Roberta DI MARCO (380 Italy), Eva DRAŽANOVÁ (203 Czech Republic, belonging to the institution), Chiara Bianca Maria PLATANIA (380 Italy), Fabio Arturo IANNOTTI (380 Italy), Jana RUDÁ (203 Czech Republic, belonging to the institution), Claudio D'ADDARIO (380 Italy), Lucie KRATKA (203 Czech Republic), Vladimír PEKAŘÍK (203 Czech Republic, belonging to the institution), Fabiana PISCITELLI (380 Italy), Zuzana BABINSKÁ (703 Slovakia, belonging to the institution), Julia FEDOTOVA (643 Russian Federation), Giovanni GIURDANELLA (380 Italy), Salvatore SALOMONE (380 Italy), Alexandra SULCOVA (203 Czech Republic), Claudio BUCOLO (380 Italy), Carsten T. WOTJAK (276 Germany), Zenon, Jr. STARCUK (203 Czech Republic), Filippo DRAGO (380 Italy), Raphael MECHOULAM (376 Israel), Vincenzo DI MARZO (380 Italy) and Vincenzo MICALE (380 Italy, guarantor).
Edition Biochemical Pharmacology, OXFORD, PERGAMON-ELSEVIER SCIENCE LTD, 2020, 0006-2952.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30104 Pharmacology and pharmacy
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 5.858
RIV identification code RIV/00216224:14110/20:00116001
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.bcp.2020.114004
UT WoS 000541248000065
Keywords in English Cannabidiol; Dopamine D3 receptor; Molecular Dynamics; Arterial Spine Labelling; MAM model; Schizophrenia
Tags 14110515, 14110516, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 7/10/2021 20:01.
Abstract
Gestational methylazoxymethanol acetate (MAM) treatment produces offspring with adult phenotype relevant to schizophrenia, including positive- and negative-like symptoms, cognitive deficits, dopaminergic dysfunction, structural and functional abnormalities. Here we show that adult rats prenatally treated with MAM at gestational day 17 display significant increase in dopamine D3 receptor (D3) mRNA expression in prefrontal cortex (PFC), hippocampus and nucleus accumbens, accompanied by increased expression of dopamine D2 receptor (D2) mRNA exclusively in the PFC. Furthermore, a significant change in the blood perfusion at the level of the circle of Willis and hippocampus, paralleled by the enlargement of lateral ventricles, was also detected by magnetic resonance imaging (MRI) techniques. Peripubertal treatment with the non-euphoric phytocannabinoid cannabidiol (30 mg/kg) from postnatal day (PND) 19 to PND 39 was able to reverse in MAM exposed rats: i) the upregulation of the dopamine D3 receptor mRNA (only partially prevented by haloperidol 0.6 mg/kg/day); and ii) the regional blood flow changes in MAM exposed rats. Molecular modelling predicted that cannabidiol could bind preferentially to dopamine D3 receptor, where it may act as a partial agonist according to conformation of ionic-lock, which is highly conserved in GPCRs. In summary, our results demonstrate that the mRNA expression of both dopamine D2 and D3 receptors is altered in the MAM model; however only the transcript levels of D3 are affected by cannabidiol treatment, likely suggesting that this gene might not only contribute to the schizophrenia symptoms but also represent an unexplored target for the antipsychotic activity of cannabidiol.
Links
EF16_013/0001775, research and development projectName: Modernizace a podpora výzkumných aktivit národní infrastruktury pro biologické a medicínské zobrazování Czech-BioImaging
LM2015062, research and development projectName: Národní infrastruktura pro biologické a medicínské zobrazování
Investor: Ministry of Education, Youth and Sports of the CR
MUNI/A/1292/2019, interní kód MUName: Preklinický a klinický výzkum studentů v oblasti farmakokinetiky, neuropsychofarmakologie a personalizované farmakoterapie v onkologii
Investor: Masaryk University, Category A
Displayed: 22/7/2024 08:24